At Palau, our R&D process starts from a deep analysis of therapeutic needs, in order to improve existing treatments and achieve meaningful differentiation as early as possible. We compare our products with established gold standard treatments or reference compounds under development. Our development process enables this approach early on in the lead optimization phase, and we continue such approach throughout the entire development process.

Palau’s drug discovery relies on the rational design and synthesis of novel small molecules that modify the functioning of innovative pharmacological targets with established preclinical or clinical proof-of-concept in the inflammatory and autoimmune-related fields. Our drug development strategy focuses on the quick reaching of the proof-of-concept, which helps minimizing the development costs.

One of our key strengths in this approach is the extensive use of specific animal models of a wide array of diseases that are designed to expedite the selection of those compounds that demonstrate the highest potential for clinical and commercial success in the market.

We actively seek worldwide patent protection for any inventions and innovations of significant commercial value that arise from our projects. A key component of our business strategy is to create a strong patent portfolio to offer the best possible protection to our projects.

In the past, our experience covered the entire development value chain, from discovery to registration to commercialization. This expertise in the end-to-end approach enables us now to manage all aspects of drug development, including formulation, manufacturing and regulatory issues.

One of our key strengths is the use of specific animal models of a wide array of diseases: